Historical valuation data is not available at this time.
Jafron Biomedical Co., Ltd. is a China-based medical device company specializing in the research, development, production, and sale of hemoperfusion products. The company's core products are used primarily for the removal of toxins and inflammatory mediators from blood in clinical settings, such as treating autoimmune diseases, severe infections, drug intoxication, and organ failure. Jafron operates mainly within the domestic Chinese market and has established itself as a key player in the hemoperfusion segment, leveraging its proprietary adsorbent materials and product portfolio. Its competitive advantages include technological expertise in adsorbent polymer materials, a comprehensive product lineup approved by China's National Medical Products Administration (NMPA), and a growing sales network within Chinese hospitals.
Focus on R&D in biomedical adsorption materials; holds multiple patents related to hemoperfusion and adsorbent technology in China
Jafron Biomedical holds a niche but growing position in China's hemoperfusion market, supported by its proprietary technology and regulatory approvals. The company benefits from demographic and healthcare trends but faces risks from regulatory changes, competition, and market concentration. Investors should monitor financial performance, regulatory updates, and expansion progress for a balanced assessment of its potential.